The U.K. Gene Therapy Advisory Committee gave ReNeuron final approval to begin a clinical trial that involves injecting fetus-derived neural stem cells into the brains of disabled stroke patients. The biotech firm plans to test the ReN001 cell therapy on 12 patients who suffered ischemic strokes.

Full Story:

Related Summaries